In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease. Andrew Fein, managing director of equity research at H.C. Wainwright, said that “the worst case scenarios have largely been taken off the table,” noting better clarity following policy moves under Donald Trump. According to Dealogic data, IPO activity fell to 10 listings in 2025, the fewest in over a decade, down from 26 in 2024 and 93 in 2021, with proceeds decreasing to $1.6 billion from $16 billion in 2021.
Sentiment improved as equities gained momentum, with David Wagner claiming pricing trends became “more optimistic” in late 2025. Kevin Eisele, managing director at William Blair, said investors are more willing to deploy capital regardless of “headline risk.” Based on Seth Rubin, head of global equity capital markets at Stifel, markets will not return to their previous highs but will become “much more robust.”
With that said, here are the 8 Most Promising Biotech Stocks to Buy Now.
Vlad Teodor/Shutterstock.com
Methodology:
We used screeners to identify Biotech stocks with an average upside potential of at least 15%, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
On April 30, Oppenheimer raised its price target on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) from $104 to $111. It maintained an “Outperform” rating on the stock while noting shares rose after first-quarter results and updated guidance.
On April 29, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported first-quarter 2026 results. Growing demand for TRYNGOLZA is driven by launch execution while raising full-year revenue guidance.
The company said the FDA accepted the olezarsen sNDA for priority review, with launch preparations for severe hypertriglyceridemia progressing, while growing peak net sales guidance for TRYNGOLZA to over $3 billion.
The pipeline advanced. The firm said the FDA accepted the “zilganersen NDA” for priority review, positioning its first independent neurology launch.
CEO Brett Monia summed it up simply by stating that the business is performing well on both the commercial and R&D fronts. He noted future Phase 3 readouts and launches for olezarsen and zilganersen this year.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a firm that develops and markets human therapeutic drugs using antisense technology. It is based in Carlsbad, California.
